Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2013; 5(4): 71-80
Published online Apr 15, 2013. doi: 10.4251/wjgo.v5.i4.71
Published online Apr 15, 2013. doi: 10.4251/wjgo.v5.i4.71
Current oncologic applications of radiofrequency ablation therapies
Dhruvil R Shah, Angelina Elliot, Vijay P Khatri, Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95815, United States
Sari Green, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA 90502, United States
John P McGahan, Department of Radiology, University of California Davis, Sacramento, CA 95815, United States
Author contributions: Shah DR analyzed the data and wrote the paper; Green S performed the background research and created a portion of the tables for the paper; Elliot A performed the background research and created a portion of the tables for the paper; McGahan JP critically reviewed the manuscript; Khatri VP designed the research and critically revised it.
Correspondence to: Vijay P Khatri, MBChB, FACS, Professor of Surgery, Division of Surgical Oncology, Department of Surgery, University of California, 4501 X Street, Sacramento, CA 95817, United States. vijay.khatri@ucdmc.ucdavis.edu
Telephone: +1-916-7342172 Fax: +1-916-7035267
Received: February 1, 2013
Revised: March 10, 2013
Accepted: March 15, 2013
Published online: April 15, 2013
Revised: March 10, 2013
Accepted: March 15, 2013
Published online: April 15, 2013
Core Tip
Core tip: We have described the technical aspects of radiofrequency ablation (RFA), advances in delivery mechanisms, indications for usage, and its equivalence or lack of equivalence to surgical resection. We emphasized studies that reported long term oncologic outcomes associated with RFA use for primary and metastatic liver and lung tumors, and described the evolving role of RFA for breast and solid renal tumors.